PGNY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Progyny Inc (PGNY) is not a strong buy for a beginner investor with a long-term horizon at this moment. While the company has shown positive financial growth in the latest quarter, the technical indicators suggest a bearish trend, and insider selling has significantly increased. Additionally, analysts have lowered price targets, reflecting cautious sentiment. The lack of recent positive news or significant catalysts further supports a hold recommendation.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 29.61, providing no clear signal. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the current price is near the support level of 16.418, suggesting potential downside risk. Overall, the technical indicators do not support a strong buy signal.
The company's financials for Q4 2025 showed growth in revenue (+6.69% YoY), net income (+18.54% YoY), EPS (+27.27% YoY), and gross margin (+13.59% YoY). Analysts have noted healthy member engagement and positive utilization trends.
Insiders are selling heavily, with a 601.40% increase in selling activity over the last month. Analysts have lowered price targets across the board, citing concerns about membership growth and broader employer demand trends. There is no recent news or event-driven catalyst to support a bullish case.
In Q4 2025, Progyny reported revenue of $318.4M (+6.69% YoY), net income of $12.49M (+18.54% YoY), EPS of $0.14 (+27.27% YoY), and gross margin of 24.15% (+13.59% YoY). These results indicate solid financial growth but are overshadowed by concerns about future membership and demand trends.
Analysts have lowered price targets significantly, with the most recent targets ranging from $19 to $30. While some analysts maintain Buy or Overweight ratings, others have downgraded to Hold, reflecting cautious sentiment due to uncertain membership growth and employer demand trends.
